+4 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Natera, Inc. Strong Buy (bullish), based on 22 analysts. Average price target: US$409.57.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 3043 declarations
Natera, Inc. accumulates 3,042 filings from 37 filers, including 1,783 sales for EUR 884,656,135, with a median of EUR 125,735, 861 option exercises and 215 grants. The three largest sales: James Healy, Director, EUR 35,036,722 on December 13, 2023, then Steven Leonard Chapman, CEO and President, EUR 27,163,848 on November 3, 2025 and EUR 14,507,260 on January 20, 2026. Steven Leonard Chapman signs 613 filings, 342 of them sales; Jonathan Sheena, Director, is the most active, with 641 filings, 468 of them sales.
The 11 purchases come to EUR 20,572,212, which is 1% of open-market trades: Roelof Botha, Director, EUR 7,008,990 on June 19, 2016 and EUR 2,552,180 on March 16, 2022, Matthew Rabinowitz, Executive Chairman, EUR 4,435,004 on May 12, 2022. On June 19, 2016, two filers bought for EUR 9,692,430. All 11 purchases have a stored 90-day result, with a median of minus 14.5% (stored results, not a forecast).
Activity has risen sharply: 14 filings in 2017, 446 in 2021, 544 in 2025 and 459 in 2026. Over the last twelve months, 574 filings, 440 of them sales and no purchase. Market capitalisation is USD 57,574,068,224.
Insider filings
Over the last 90 days, 181 filings published between 27 July and 21 October 2026: 143 sales for €91.6M. 38 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: Rabinowitz Matthew (EXECUTIVE CHAIRMAN), sales of €63.3M; Sheena Jonathan (Director), sales of €13.8M; Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS), sales of €7.5M.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 23 October 2026 (UTC)
Headquarters: San Carlos, United States · Founded: 2004 · Wikipedia article
Source: Wikidata (CC0).
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 2.31 bn USD | -208.2 m USD | -1.52 USD | 10-K |
| Dec 2024 | 1.70 bn USD | -190.4 m USD | -1.53 USD | 10-K |
| Dec 2023 | 1.08 bn USD | -434.8 m USD | -3.78 USD | 10-K |
| Dec 2022 | 820.2 m USD | -547.8 m USD | -5.57 USD | 10-K |
| Dec 2021 | 625.5 m USD | -471.7 m USD | -5.21 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.